CC BY-NC-ND 4.0 · Asian J Neurosurg 2024; 19(02): 107-111
DOI: 10.1055/s-0043-1777264
Review Article

Does New WHO 2022 Nomenclature of Pituitary Neuroendocrine Tumors Offer an Extra Edge to the Neurosurgeons for Its Management? A Narrative Review

1   Department of Neurosurgery, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India
Manish Singh
1   Department of Neurosurgery, Ganesh Shankar Vidyarthi Memorial Medical College, Kanpur, Uttar Pradesh, India
Awadhesh Yadav
2   Department of Neurosurgery, King George's Medical University, Lucknow, Uttar Pradesh, India
Chhitij Srivastava
2   Department of Neurosurgery, King George's Medical University, Lucknow, Uttar Pradesh, India
Anil Chandra
2   Department of Neurosurgery, King George's Medical University, Lucknow, Uttar Pradesh, India
Akanksha D. Srivastava
3   Department of Paediatrics, King George's Medical University, Lucknow, Uttar Pradesh, India
› Author Affiliations
Funding None.


The new World Health Organization nomenclature of pituitary tumors was introduced in the year 2022 after much deliberation. This nomenclature clearly demarcates the anterior lobe (adenohypophyseal), posterior lobe (neurohypophyseal), and hypothalamic tumors. There is also focus on other tumors arising in the sellar region. The nomenclature has also advocated the routine use of immunohistochemistry in describing the pituitary transcription factors that plays a fundamental role in distinguishing the cell lineage of these tumors. However, the nomenclature is complex in understanding due to inclusion of pathological correlates like transcription factors, hormones, biomarkers, and various controversies that have emerged regarding the renaming of pituitary adenomas (PA) as PiTNETs (“Pituitary Neuroendocrine tumors”) because majority of the adenomas are benign and have rare metastatic behavior while classifying them as PiTNETs will create unnecessary misinterpretation of these as aggressive tumors that will lead to apprehension among the patients. The new classification gives deeper insight into the histological picture of the various pituitary tumors but other than contributing to the follow-up strategy and postsurgery management, this classification does not add anything new that could be advantageous for the neurosurgeons in clinical practice and decision making, especially in deciding the plan of action for surgery. Hence, there is need of a more comprehensive, integrated, neuroradiological-based classification with more emphasis on the invasiveness of these tumors that would assist the neurosurgeons in planning the treatment strategy and managing patients of pituitary tumors.

Publication History

Article published online:
10 June 2024

© 2024. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Asa SL, Perry A. (2020) Tumors of the Pituitary Gland. AFIP Atlas of Tumor and Non-Tumor Pathology. Arlington VA: ARP Press;
  • 2 Osamura RY, Kajiya H, Takei M. et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008; 130 (03) 495-507
  • 3 Jentoft ME, Osamura RY, Kovacs K, Lloyd RV, Scheithauer BW. Transdifferentiation of pituitary thyrotrophs to lactothyrotrophs in primary hypothyroidism: case report. Virchows Arch 2012; 461 (02) 221-225
  • 4 Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7 (05) 257-266
  • 5 Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro-oncol 2017; 19 (06) 762-773
  • 6 Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72 (03) 377-382
  • 7 Agustsson TT, Baldvinsdottir T, Jonasson JG. et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol 2015; 173 (05) 655-664
  • 8 Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 2022; 33 (01) 6-26
  • 9 Neou M, Villa C, Armignacco R. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 2020; 37 (01) 123-134.e5
  • 10 Lloyd RV, Kovacs K, Young WF. Pitutary tumours: Introduction. In: WHO Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C. , eds. Chapter 1: Tumours of Pituitary; WHO: Lyon, France; 2004: 10-13
  • 11 Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new?. Acta Neuropathol 2006; 111 (01) 1-7
  • 12 Villa C, Vasiljevic A, Jaffrain-Rea ML. et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch 2019; 475 (06) 687-692
  • 13 Nishioka H, Inoshita N. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathol 2018; 35 (02) 57-61
  • 14 Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 2017; 134 (04) 521-535
  • 15 Tiwari S, Pant I, Chaturvedi S. Pituitary tumors: changing paradigms in understanding, nomenclature and the newer basis of classification. Astrocyte 2018; 4 (04) 240
  • 16 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to classify pituitary neuroendocrine tumors (PitNET) s in 2020. Cancers (Basel) 2020; 12 (02) 514
  • 17 Asa SL, Casar-Borota O, Chanson P. et al; attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24 (04) C5-C8
  • 18 Ho KKY, Fleseriu M, Wass J. et al. A tale of pituitary adenomas: to NET or not to NET: pituitary Society position statement. Pituitary 2019; 22 (06) 569-573
  • 19 Rindi G, Klimstra DS, Abedi-Ardekani B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31 (12) 1770-1786
  • 20 Mete O, Kefeli M, Çalışkan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019; 32 (04) 484-489
  • 21 Punsoni M, Asa SL. Pituitary neuroendocrine tumor (PitNET). website. . Accessed November 7, 2023 at:
  • 22 Nickel B, Semsarian C, Moynihan R. et al. Public perceptions of changing the terminology for low-risk thyroid cancer: a qualitative focus group study. BMJ Open 2019; 9 (02) e025820
  • 23 Dai C, Kang J, Liu X, Yao Y, Wang H, Wang R. How to classify and define pituitary tumors: recent advances and current controversies. Front Endocrinol (Lausanne) 2021; 12: 604644
  • 24 Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018; 31 (06) 900-909
  • 25 Hong SW, Kim SH, Lim SH. et al. Clinical relevance of New World Health Organization classification system for pituitary adenomas: a validation study with 2-year experience. Front Oncol 2021; 11: 739290
  • 26 Kim J, Yoon SJ, Moon JH. et al. Clinical significance of radical surgery in the treatment of silent corticotroph adenoma. J Korean Neurosurg Soc 2019; 62 (01) 114-122
  • 27 Wan XY, Chen J, Wang JW, Liu YC, Shu K, Lei T. Overview of the 2022 WHO classification of pituitary adenomas/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives. Curr Med Sci 2022; 42 (06) 1111-1118